Head-to-head · free
Concentra vs Dianthus Therapeutics, Inc.
CON vs DNTH — return on capital, cash generation, margins and balance sheet side by side.
CON
5 / 6
measures where CON leads
DNTH
1 / 6
measures where DNTH leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | CON · FY2025 | DNTH · FY2025 |
|---|---|---|
| Revenue | $2.2B | $2.0M |
| Net income | $166.4M | (162.3M) |
| Revenue growth (yearly, multi-year) | 13.9% | -67.3% |
| Free cash flow | $197.1M | — |
| Free cash flow margin | 9.1% | — |
| Net cash / (debt) | — | — |
| ROIC | 10.8% | — |
| Return on equity | 49.8% | -38.4% |
| Gross margin | 28.3% | — |
| Operating margin | 15.4% | -8739.3% |
| Net debt / EBITDA | 3.65x | 0.29x |
Figures are as reported by each company; latest fiscal year shown.
Where Concentra's cash went (FY2025)
- Capital spending
- $82.3M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Dianthus Therapeutics, Inc.'s cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free